Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells

FEBS Journal

Volumn 272, Issue 3, 2005, Pages 696-710

  Peñuelas, Silvia ^a   Noé, Véronique ^a   Ciudad, Carlos J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

IMPDH2; Methotrexate; Survivin; TOP1; Vimentin

Indexed keywords

BENZAMIDE; CADHERIN; CYCLINE; DNA TOPOISOMERASE; FIBROBLAST GROWTH FACTOR 5; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSINATE DEHYDROGENASE; KERATIN; LACTATE DEHYDROGENASE; METHOTREXATE; MYC PROTEIN; MYCOPHENOLIC ACID; NUCLEOSIDE DIPHOSPHATE KINASE; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PROTEIN FOS; PROTEIN P19; PURINE NUCLEOSIDE PHOSPHORYLASE; RETINOID X RECEPTOR BETA; STRESS ACTIVATED PROTEIN KINASE; SUMO 1 PROTEIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TENASCIN; THYMIDYLATE SYNTHASE; TIAZOFURIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR E2F1; VIMENTIN; ZINC FINGER PROTEIN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL MOTILITY; CELL STRAIN HT29; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; CYTOTOXICITY; DNA MICROARRAY; DNA RECOMBINATION; DNA REPAIR; DNA SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; METABOLISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; BLOTTING, WESTERN; COLONIC NEOPLASMS; DNA PRIMERS; DNA TOPOISOMERASES, TYPE I; DNA, COMPLEMENTARY; HT29 CELLS; HUMANS; IMP DEHYDROGENASE; METHOTREXATE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIMENTIN;

EID: 13444269172     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2004.04504.x     Document Type: Article

References (62)

1. Huennekens FM (1994) The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 34, 397-419.
2. Goldman ID & Matherly LH (1985) The cellular pharmacology of methotrexate. Pharmacol Ther 28, 77-102.
3. Wagner C (1996) Symposium on the subcellular compartmentation of folate metabolism. J Nutr 126, 1228S-1234S.
4. Chu E, Grem JL, Johnston PG & Allegra CJ (1996) New concepts for the development and use of anti-folates. Stem Cells 14, 41-46.
5. Alt FW, Kellems RE, Bertino JR & Schimke RT (1978) Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253, 1357-1370.
6. Dicker AP, Volkenandt M, Schweitzer BI, Banerjee D & Bertino JR (1990) Identification and characterization of a mutation in the dihydrofolate reductase gene from the methotrexate-resistant Chinese hamster ovary cell line Pro-3 MtxRIII. J Biol Chem 265, 8317-8321.
7. Yu M & Melera PW (1993) Allelic variation in the dihydrofolate reductase gene at amino acid position 95 contributes to antifolate resistance in Chinese hamster cells. Cancer Res 53, 6031-6035.
8. Srimatkandada S, Schweitzer BI, Moroson BA, Dube S & Bertino JR (1989) Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. J Biol Chem 264, 3524-3528.
9. Dixon KH, Lanpher BC, Chiu J, Kelley K & Cowan KH (1994) A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem 269, 17-20.
10. Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M, Priest DG, Noordhuis P, Schornagel JH, Pinedo HM, Peters GJ & Assaraf YG (1998) A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 273, 30189-30198.
11. Roy K, Tolner B, Chiao JH & Sirotnak FM (1998) A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells. J Biol Chem 273, 2526-2531.
12. Zhao R, Sharina IG & Goldman ID (1999) Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol Pharmacol 56, 68-76.
13. Roy K, Egan MG, Sirlin S & Sirotnak FM (1997) Post-transcriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of the L1210 cell. Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of the enzyme. J Biol Chem 272, 6903-6908.
14. Rhee MS, Wang Y, Nair MG & Galivan J (1993) Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res 53, 2227-2230.
15. Curt GA, Cowan KH & Chabner BA (1984) Gene amplification in drug resistance: of mice and men. J Clin Oncol 2, 62-64.
16. Carman MD, Schornagel JH, Rivest RS, Srimatkandada S, Portlock CS, Duffy T & Bertino JR (1984) Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 2, 16-20.
17. de Nonancourt-Didion M, Gueant JL, Adjalla C, Chery C, Hatier R & Namour F (2001) Overexpression of folate binding protein alpha is one of the mechanism explaining the adaptation of HT29 cells to high concentration of methotrexate. Cancer Lett 171, 139-145.
18. Lesuffleur T, Barbat A, Luccioni C, Beaumatin J, Clair M, Kornowski A, Dussaulx E, Dutrillaux B & Zweibaum A (1991) Dihydrofolate reductase gene amplification-associated shift of differentiation in methotrexate-adapted HT-29 cells. J Cell Biol 115, 1409-1418.
19. Coma S, Noé V, Lavarino C, Adán J, Rivas M, López-Matas M, Pagan F, Mitjans F, Senén V, Piulats J & Ciudad CJ (2004) Utilization of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides 14, 100-113.
20. Kaiser WA, Herrmann B & Keppler DO (1980) Selective guanosine phosphate deficiency in hepatoma cells induced by inhibitors of IMP dehydrogenase. Hoppe Seylers Z Physiol Chem 361, 1503-1510.
21. Hager PW, Collart FR, Huberman E & Mitchell BS (1995) Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 49, 1323-1329.
22. Zimmermann A, Gu JJ, Spychala J & Mitchell BS (1996) Inosine monophosphate dehydrogenase expression: transcriptional regulation of the type I and type II genes. Adv Enzyme Regul 36, 75-84.
23. Zhao R & Goldman ID (2003) Resistance to antifolates. Oncogene 22, 7431-7457.
24. White JC & Goldman ID (1976) Mechanism of action of methotrexate. IV. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Ehrlich ascites tumor cells in vitro. Mol Pharmacol 12, 711-719.
25. Seither RL, Trent DF, Mikulecky DC, Rape TJ & Goldman ID (1989) Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells. J Biol Chem 264, 17016-17023.
26. Adjei AA (2004) Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 5 (Suppl. 2), S51-S55.
27. Longo-Sorbello GS & Bertino JR (2001) Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 86, 121-127.
28. Deveraux QL & Reed JC (1999) IAP family proteins - suppressors of apoptosis. Genes Dev 13, 239-252.
29. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T & Reed JC (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58, 5315-5320.
30. Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Ong K, Baens M, Collen D & Schuh AC (2000) Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 95, 1435-1442.
31. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK & Oh BH (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40, 1117-1123.
32. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC & Altieri DC (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97, 13103-13107.
33. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I & Reed JC (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. Embo J 22, 2729-2740.
34. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K, Nakano T, Miura M & Shiraki K (2000) Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19, 1346-1353.
35. Tarnawski AS & Szabo I (2001) Apoptosis-programmed cell death and its relevance to gastrointestinal epithelium: survival signal from the matrix. Gastroenterology 120, 294-299.
36. Ambrosini G, Adida C & Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3, 917-921.
37. Chiou SK, Moon WS, Jones MK & Tarnawski AS (2003) Survivin expression in the stomach: implications for mucosal integrity and protection. Biochem Biophys Res Commun 305, 374-379.
38. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF & Wong BC (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63, 7724-7732.
39. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R & Potmesil M (1989) DNA topoisomerase I - targeted chemotherapy of human colon cancer in xenografts. Science 246, 1046-1048.
40. Husain I, Mohler JL, Seigler HF & Besterman JM (1994) Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54, 539-546.
41. O'Leary J & Muggia FM (1998) Camptothecins: a review of their development and schedules of administration. Eur J Cancer 34, 1500-1508.
42. Takimoto CH, Wright J & Arbuck SG (1998) Clinical applications of the camptothecins. Biochim Biophys Acta 1400, 107-119.
43. Wang CY, Cusack JC Jr, Liu R & Baldwin AS Jr (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5, 412-417.
44. Majumdar S & Aggarwal BB (2001) Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 167, 2911-2920.
45. Byun Y, Chen F, Chang R, Trivedi M, Green KJ & Cryns VL (2001) Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ 8, 443-450.
46. Morishima N (1999) Changes in nuclear morphology during apoptosis correlate with vimentin cleavage by different caspases located either upstream or downstream of Bcl-2 action. Genes Cells 4, 401-414.
47. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P & Semenza GL (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63, 1138-1143.
48. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S & Singh G (2003) Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 63, 2306-2311.
49. Wilson KS, Roberts H, Leek R, Harris AL & Geradts J (2002) Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol 161, 1171-1185.
50. Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellers TA & Hendrix MJ (1999) Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin Cancer Res 5, 2698-2703.
51. Domagala W, Lasota J, Bartkowiak J, Weber K & Osborn M (1990) Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 136, 219-227.
52. Conforti G, Codegoni AM, Scanziani E, Dolfini E, Dasdia T, Calza M, Caniatti M & Broggini M (1995) Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. Br J Cancer 71, 505-511.
53. Bichat F, Mouawad R, Solis-Recendez G, Khayat D & Bastian G (1997) Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line. Anticancer Res 17, 3393-3401.
54. Dahiya R, Lesuffleur T, Kwak KS, Byrd JC, Barbat A, Zweibaum A & Kim YS (1992) Expression and characterization of mucins associated with the resistance to methotrexate of human colonic adenocarcinoma cell line HT29. Cancer Res 52, 4655-4662.
55. Walsh MD, Luckie SM, Cummings MC, Antalis TM & McGuckin MA (1999) Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res Treat 58, 255-266.
56. Rocke DM & Durbin B (2001) A model for measurement error for gene expression arrays. J Comput Biol 8, 557-569.
57. Noé V, Alemany C & Ciudad CJ (1995) Determination of dihydrofolate reductase gene amplification from single cell colonies by quantitative polymerase chain reaction. Anal Biochem 224, 600-603.
58. Kraus MH, Popescu NC, Amsbaugh SC & King CR (1987) Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. Embo J 6, 605-610.
59. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
60. Noé V, MacKenzie S & Ciudad CJ (2003) An intron is required for dihydrofolate reductase protein stability. J Biol Chem 278, 38292-38300.
61. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63.
62. Rodriguez M, Noé V, Alemany C, Miralles A, Bemi V, Caragol I & Ciudad CJ (1999) Effects of anti-sense oligonucleotides directed toward dihydrofolate reductase RNA in mammalian cultured cells. Int J Cancer 81, 785-792.